OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results

Rhea-AI Summary

OptimizeRx (OPRX) reported strong Q4 2024 results with revenue increasing 14% year-over-year to $32.3 million. Q4 gross profit grew 23% to $22.0 million with a 68% margin. Full-year 2024 revenue reached $92.1 million, up 29% from 2023.

The company doubled its DAAP deals from 24 in 2023 to 48 in 2024. Q4 non-GAAP net income was $5.5 million ($0.30 per diluted share), while Adjusted EBITDA increased 53% to $8.8 million. Full-year GAAP net loss was $(20.1) million.

Looking ahead, OptimizeRx provided 2025 guidance with expected revenue of at least $100 million and Adjusted EBITDA of at least $12 million. The company is transitioning DAAP customers to a subscription-based model for data services to improve margins and reduce business cyclicality.

Positive

• Q4 revenue grew 14% YoY to $32.3M
• Full-year revenue increased 29% to $92.1M
• Q4 gross profit up 23% with 68% margin
• DAAP deals doubled from 24 to 48 in 2024
• Q4 Adjusted EBITDA up 53% to $8.8M
• Strong 2025 guidance: $100M+ revenue
• Positive operating cash flow of $4.9M

Negative

• Full-year GAAP net loss of $(20.1M)
• Q4 GAAP net loss of $(0.1M)
• Cash position relatively low at $13.4M

Insights

Financial Analyst

OptimizeRx's Q4 and full-year 2024 results demonstrate impressive growth momentum with revenue increasing 14% year-over-year to $32.3 million for Q4 and 29% growth to $92.1 million for the full year. More notably, the company's profitability metrics show significant improvement with Q4 gross profit jumping 23% to $22.0 million and gross margin reaching 68%.

The company's adjusted EBITDA for Q4 surged 53% to $8.8 million, indicating strong operational efficiency improvements. While non-GAAP figures look promising with $5.5 million Q4 non-GAAP net income ($0.30 per diluted share), it's important to note that GAAP results still show net losses of $0.1 million for Q4 and $20.1 million for the full year.

The doubling of DAAP deals from 24 in 2023 to 48 in 2024 represents significant market penetration and customer acquisition success. OptimizeRx's strategic pivot toward a subscription-based model for data services should create more predictable revenue streams, reduce business cyclicality, and potentially improve margins – a critical evolution for healthcare technology providers.

With $13.4 million in cash and positive operating cash flow of $4.9 million for 2024, the company appears well-positioned for continued growth. The 2025 guidance of at least $100 million in revenue suggests continued, though more modest, growth trajectory with a focus on operational excellence.

Business Strategy Expert

OptimizeRx's performance demonstrates successful execution of its healthcare technology platform strategy at the intersection of life sciences and digital healthcare. The company's 68% gross margin is particularly impressive for a technology platform business, indicating strong operational leverage and value creation.

The announced transition to a subscription-based model for data services represents a strategically sound evolution that addresses several business challenges simultaneously. This shift should reduce revenue volatility, increase customer retention, and create more predictable financial performance – qualities highly valued by both customers and investors.

The dramatic increase in DAAP deals (48 in 2024 versus 24 in 2023) indicates strong product-market fit and effective commercial execution. As healthcare continues its digital transformation, OptimizeRx appears well-positioned to capitalize on pharma's increasing need for digital engagement with healthcare professionals.

The CEO's reference to becoming a "Rule of 40 company" (where growth rate plus profit margin exceeds 40%) signals ambitious but potentially achievable goals given their current trajectory. The focus on customer-centricity and operational excellence aligns with best practices for platform businesses.

With the company trading at a market cap of approximately $76 million on $92.1 million in annual revenue (a price-to-sales ratio below 1.0), the market appears to be discounting OptimizeRx's growth potential and strategic positioning, possibly due to GAAP profitability concerns. If the company can successfully transition to its subscription model while maintaining growth, this valuation gap may present opportunity.

• Q4 revenue of $32.3 million, increasing 14% year-over-year
• Q4 gross profit increased 23% year-over-year to $22.0 million with gross margin of 68%
• Company generated revenue from 48 DAAP deals in 2024, up from 24 in 2023

WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended December 31, 2024.

	For the Year Ended December 31,
Key Performance Indicators (KPIs)*		2024				2023
	(in thousands, except percentages)
Average revenue per top 20 pharmaceutical manufacturer	$	2,933			$	2,399
Percent of top 20 pharmaceutical manufacturers that are customers		100	%			100	%
Percent of total revenue attributable to top 20 pharmaceutical manufacturers		64	%			67	%
Net revenue retention		121	%			105	%
Revenue per average full-time employee	$	701			$	586

Stephen L. Silvestro, OptimizeRx CEO commented, "I’m incredibly proud of our strong fourth quarter and full year 2024 results and the momentum that we've achieved since we reported third quarter results last November, including, among our other successes, that we surpassed our expectations as well as consensus estimates. With the strong tailwinds we saw at the end of 2024 and into the start of 2025, we believe we are uniquely positioned to grow shareholder value by leveraging our industry leadership position in addressing pharma's most critical commercial challenges: improving brand visibility in an increasingly digital healthcare environment, reducing script abandonment rates, enhancing interoperability at the point of care, and supporting the shift toward complex specialty medications."

"As the success of our ongoing transformation becomes more reflected in our financial results, now more than ever, we will be laser-focused on operational excellence and disciplined execution while ensuring we delight our customers and forge stronger relationships with valued business partners. Over the past few months, we have completed an extensive strategic review of the Company’s business processes, operations, revenue model, and growth plans and believe we are on the right path forward for shareholder value creation. As we move through fiscal 2025 and leverage the strong momentum we had in 2024, we plan to continue the Company’s growth and transformation, focusing very closely on customer-centricity and delight, continuing to expand our unique value proposition with pharma, positioning OptimizeRx to become a “Rule of 40 company,” and unlocking new opportunities for profitable revenue growth and shareholder value creation. A key component of our strategy includes transitioning our DAAP customers to a more predictable subscription-based model for data services, which we expect will improve margins, increase visibility, reduce the cyclical nature of our business, and facilitate our ability to more effectively scale."

Financial Highlights

• Revenue in the fourth quarter of 2024 increased 14% to $32.3 million, from $28.4 million in the same period of 2023, with the full year revenue coming in at $92.1 million, a 29% increase when compared to the same year-ago period.
• Gross profit in the fourth quarter of 2024 increased 23% year-over-year to $22.0 million. Gross profit for the full year came in at $59.4 million.
• GAAP net (loss) in the fourth quarter totaled $(0.1) million or $0.00 per basic and diluted share and GAAP net (loss) for the full year totaled $(20.1) million or $(1.10) per basic and diluted share.
• Non-GAAP net income in the fourth quarter totaled $5.5 million or $0.30 per diluted share and came in at $6.2 million or $0.34 per diluted share for the full year (see *Non-GAAP Measures below).
• Adjusted EBITDA for the fourth quarter came in at $8.8 million a 53% increase from the $5.8 million we recognized during the same year-ago period. Adjusted EBITDA for the full year came in at $11.7 million (see *Non-GAAP Measures below).
  

• Cash and cash equivalents was $13.4 million as of December 31, 2024.
  

• Net cash provided by operating activities was $4.9 million for the year ended December 31, 2024.
  

Financial Outlook

The Company is providing full year 2025 guidance and expects revenue to be at least $100 million with an Adjusted EBITDA of at least $12 million.

Conference Call, Webcast, and Webcast Replay Information

Date: Wednesday, March 12, 2025
Time: 8:30 a.m. Eastern Time
Toll Free: 1-844-825-9789
International: 1-412-317-5180
Conference ID: 10197021
Call Me: https://callme.viavid.com/?$Y2FsbG1lPXRydWUmcGFzc2NvZGU9JmluZm89Y29tcGFueSZyPXRydWUmYj0xNg==
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1708545&tp_key=86684771bf
Call Me Passcode: 2202248
Webcast Replay: The archived webcast will be on the investor relations section of the OptimizeRx website

Individual Meeting Invitation

In an effort to increase relations with institutional investors, OptimizeRx management has dedicated time to hosting individual meetings with portfolio managers and analysts. If you are interested in scheduling a meeting with OptimizeRx management, please contact: adsilva@optimizerx.com or svonderweid@lifesciadvisors.com.

*Non-GAAP Measures

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures. The reasons why we believe these measures provide useful information to investors and, for historical periods, a reconciliation of these measures to the most directly comparable GAAP measures are included in the supplemental tables that follow.

Although the Company provides guidance for Adjusted EBITDA, a non-GAAP financial measure, it is not able to provide guidance to the most directly comparable GAAP measure. Reconciliations for forward-looking figures would require unreasonable effort at this time because of the uncertainty and variability of the nature and amount of certain components of various necessary GAAP components, including, for example, those related to compensation, acquisition expenses, amortization or others that may arise during the year, and the Company’s management believes such reconciliations would imply a degree of precision that would be confusing or misleading to investors. For the same reasons, the Company is unable to address the probable significance of the unavailable information.

**Definition of Key Performance Indicators

Top 20 pharmaceutical manufacturers: We have updated the definition of “top 20 pharmaceutical manufacturers” in our key performance indicators to be based upon Fierce Pharma’s most updated list of “The top 20 pharma companies by 2023 revenue”. We previously used “The top 20 pharma companies by 2022 revenue”. As a result of this change, prior periods have been restated for comparative purposes.

Net revenue retention: Net revenue retention is a comparison of revenue generated from all clients in the previous period to total revenue generated from the same clients in the following year (i.e., excludes new client relationships for the most recent year).

Revenue per average full-time employee: We define revenue per average full-time employee (FTE) as total revenue over the last 12 months (LTM) divided by the average number of employees over the LTM, which is calculated by taking our total number of FTEs at the end of the prior year period by our total FTE headcount at the end of the most recent period.

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

For more information, follow the Company on Twitter, LinkedIn or visit www.optimizerx.com. 

Important Cautions Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans, future performance, expected revenues, expected Adjusted EBITDA, plans to grow shareholder value creation, plans to continue the Company’s growth and transformation, plans for unlocking new opportunities for profitable revenue growth, plans for expanding the Company’s value proposition with pharma, plans to position the Company to become a “Rule of 40” company, plans for forging stronger relationships with valued business partners, other business plans and operating and financial performance objectives, and other statements relating to future performance, plans, and expectations. These forward-looking statements are based on the Company’s current expectations and involve assumptions regarding the Company’s business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. ,Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with electronic prescription platforms and electronic health records networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, its subsequent Quarterly Reports on Form 10-Q, and in other filings the Company has made and may make with the Securities and Exchange Commission in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

OptimizeRx Contact
Andy D’Silva, SVP Corporate Finance
adsilva@optimizerx.com

Investor Relations Contact
Sandya von der Weid
LifeSci Advisors, LLC
svonderweid@lifesciadvisors.com

OPTIMIZERX CORPORATION CONSOLIDATED BALANCE SHEETS (in thousands except share and per share data)
	December 31,
		2024				2023
ASSETS
Current Assets
Cash and cash equivalents	$	13,380			$	13,852
Accounts receivable, net of allowance for credit losses of $335 and $239 at December 31, 2024 and 2023, respectively		38,212				36,253
Taxes receivable		—				1,036
Prepaid expenses and other		2,379				3,190
Total Current Assets		53,971				54,331
Property and equipment, net		150				149
Other Assets
Goodwill		70,869				78,357
Patent rights, net		5,517				6,185
Technology assets, net		8,180				9,013
Tradename and customer relationships, net		31,819				34,198
Operating lease right-of-use assets		366				573
Security deposits and other assets		296				568
Total Other Assets		117,047				128,894
TOTAL ASSETS	$	171,168			$	183,374
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Current portion of long-term debt	$	2,000			$	2,000
Accounts payable – trade		2,156				2,227
Accrued expenses		8,486				7,706
Revenue share payable		5,053				5,506
Taxes payable		318				49
Current portion of lease liabilities		168				222
Deferred revenue		473				172
Total Current Liabilities		18,654				17,882
Non-Current Liabilities
Long-term debt, net		30,816				34,231
Lease liabilities, net of current portion		209				371
Deferred tax liabilities, net		4,491				4,337
Total Liabilities		54,170				56,821
Commitments and contingencies
Stockholders’ Equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at December 31, 2024 and 2023, respectively		—				—
Common stock, $0.001 par value, 166,666,667 shares authorized, 20,194,697 and 19,899,679 shares issued at December 31, 2024 and 2023, respectively		20				20
Treasury stock, $0.001 par value,1,741,397 shares purchased at December 31, 2024 and 2023		(2	)			(2	)
Additional paid-in-capital		201,348				190,793
Accumulated deficit		(84,368	)			(64,258	)
Total Stockholders’ Equity	$	116,998			$	126,553
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	171,168			$	183,374

OPTIMIZERX CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands except share and per share data)
	For the Three Months Ended December 31,								For the Year Ended December 31,
		2024				2023				2024				2023
Net revenue	$	32,317			$	28,369			$	92,127			$	71,522
Cost of revenues, exclusive of depreciation and amortization presented separately below		10,293				10,528				32,749				28,622
Gross profit		22,024				17,841				59,378				42,900
Operating Expenses
Stock-based compensation		2,937				2,627				11,467				13,717
Loss on disposal of a business		—				2,142				—				2,142
Depreciation and amortization		1,094				1,006				4,329				2,402
Impairment charges		—				6,738				7,489				6,738
Other sales, general and administrative expenses		14,358				16,231				49,799				44,303
Total operating expenses		18,389				28,744				73,084				69,302
Loss from operations		3,635				(10,903	)			(13,706	)			(26,402	)
Other income (expense)
Interest expense		(1,563	)			(1,454	)			(6,160	)			(1,454	)
Other income		41				500				153				500
Interest income		96				118				328				2,192
Total other income (expense), net		(1,426	)			(836	)			(5,679	)			1,238
Income (loss) before provision for income taxes		2,209				(11,739	)			(19,385	)			(25,164	)
Income tax (expense) benefit		(2,286	)			7,598				(725	)			7,598
Net loss	$	(77	)		$	(4,141	)		$	(20,110	)		$	(17,566	)
Weighted average number of shares outstanding – basic		18,418,519				17,769,670				18,292,935				17,124,801
Weighted average number of shares outstanding – diluted		18,418,519				17,769,670				18,292,935				17,124,801
Loss per share – basic	$	—			$	(0.23	)		$	(1.10	)		$	(1.03	)
Loss per share – diluted	$	—			$	(0.23	)		$	(1.10	)		$	(1.03	)

OPTIMIZERX CORPORATION CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)
	For the Year Ended December 31,
		2024				2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(20,110	)		$	(17,566	)
Adjustments to reconcile net loss to net cash provided by / (used in) operating activities:
Depreciation and amortization		4,329				2,402
Impairment charges		7,489				6,738
Loss on disposal of business		—				2,142
Bad debt expense		209				666
Stock-based compensation		11,466				13,717
Amortization of debt issuance costs		835				211
Change in:
Accounts receivable		(2,168	)			(8,713	)
Prepaid expenses and other assets		811				(573	)
Accounts payable		(72	)			(1,320	)
Revenue share payable		(453	)			1,515
Accrued expenses and other liabilities		1,053				1,303
Deferred tax liabilities		1,449				(7,695	)
Deferred loan fees		(250	)
Deferred revenue		301				(67	)
NET CASH PROVIDED BY / (USED IN) OPERATING ACTIVITIES		4,889				(7,240	)
CASH FLOWS USED IN INVESTING ACTIVITIES:
Purchases of property and equipment		(112	)			(87	)
Proceeds from sale of property and equipment		—				10
Cash paid for acquisitions, net of cash acquired		—				(82,947	)
Proceeds from sale of business		—				2,540
Purchase of short-term investments		—				(162,778	)
Redemptions of short-term investments		—				218,709
Capitalized software development costs and other		(338	)			(784	)
NET CASH USED IN INVESTING ACTIVITIES		(450	)			(25,337	)
CASH FLOWS (USED IN) / PROVIDED BY FINANCING ACTIVITIES:
Proceeds from long-term debt, net of issuance costs		—				37,730
Repayment of long-term debt		(4,000	)			(1,710	)
Repurchase of common stock		—				(7,522	)
Cash paid for employee withholding taxes related to the vesting of restricted stock units		(911	)			—
Proceeds from exercise of stock options, net of cash paid for withholding taxes		—				(278	)
NET CASH (USED IN) / PROVIDED BY FINANCING ACTIVITIES		(4,911	)			28,220
NET DECREASE IN CASH AND CASH EQUIVALENTS		(472	)			(4,357	)
CASH AND CASH EQUIVALENTS – BEGINNING OF PERIOD		13,852				18,209
CASH AND CASH EQUIVALENTS – END OF PERIOD	$	13,380			$	13,852
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	$	6,203			$	1,213
ROU assets obtained in exchange for lease obligations	$	—			$	460
Shares issued in connection with acquisition	$	—			$	12,091
Cash paid for income taxes	$	161			$	48

OPTIMIZERX CORPORATION
RECONCILIATION of NON-GAAP to GAAP FINANCIAL MEASURES
(in thousands, except share and per share data)

This earnings release includes certain financial measures not derived in accordance with generally accepted accounting principles (GAAP). These non-GAAP financial measures are measures of performance not defined by accounting principles generally accepted in the United States and should be considered in addition to, not in lieu of, GAAP reported measures. Additionally, these non-GAAP measures may not be comparable to similarly titled measures reported by other companies. However, management believes that presenting certain non-GAAP financial measures provides additional information to facilitate comparison of the Company's historical operating results and trends in its underlying operating results and provides transparency on how the Company evaluates its business. Management uses these non-GAAP financial measures in making financial, operating and planning decisions and in evaluating the Company's performance. Management believes that financial information excluding certain items that are not considered to reflect the Company’s ongoing operating results, such as those listed below, improves the comparability of year-to-year results. Consequently, management believes that investors may be able to better understand the Company’s operating results excluding these items. Non-GAAP financial measures may reflect adjustments for items such as asset impairment charges, amortization, stock-based compensation, acquisition expenses, severance, deferred income taxes, as well as other items that management believes are not related to the Company’s ongoing performance.

	For the Three Months Ended December 31,								For the Twelve Months Ended December 31,
		2024				2023				2024				2023
Net loss	$	(77	)		$	(4,141	)		$	(20,110	)		$	(17,566	)
Deferred income taxes		153				(7,695	)			153				(7,695	)
Depreciation and amortization		1,094				1,006				4,329				2,402
Stock-based compensation		2,937				2,627				11,467				13,717
Asset impairment charges		—				6,738				7,489				6,738
Loss on disposal of business		—				2,142				—				2,142
Severance charges		1,183				288				1,908				495
Other income		(40	)			(500	)			(152	)			(500	)
Amortization of debt issuance costs		288				211				835				211
Acquisition expense		—				3,902				243				4,482
Non-GAAP net income		5,538				4,578				6,162				4,425
Non-GAAP net income per share
Diluted	$	0.30			$	0.26			$	0.33			$	0.26
Weighted average shares outstanding:
Diluted		18,464,605				17,789,235				18,583,936				17,191,300

	For the Three Months Ended December 31,								For the Twelve Months Ended December 31,
		2024				2023				2024				2023
Net loss	$	(77	)		$	(4,141	)		$	(20,110	)		$	(17,566	)
Depreciation and amortization		1,094				1,006				4,329				2,402
Stock-based compensation		2,937				2,627				11,467				13,717
Asset impairment charges		—				6,738				7,489				6,738
Loss on disposal of business		—				2,142				—				2,142
Severance charges		1,183				288				1,908				495
Acquisition expense		—				3,902				243				4,482
Other income		(40	)			(500	)			(152	)			(500	)
Interest expense (income), net		1,466				1,336				5,831				(738	)
Income tax expense (benefit)		2,286				(7,598	)			725				(7,598	)
Adjusted EBITDA		8,849				5,800				11,730				3,574

FAQ

What was OptimizeRx (OPRX) Q4 2024 revenue growth?

OptimizeRx's Q4 2024 revenue grew 14% year-over-year to $32.3 million.

How many DAAP deals did OptimizeRx secure in 2024?

OptimizeRx secured 48 DAAP deals in 2024, up from 24 deals in 2023.

What is OptimizeRx's revenue guidance for 2025?

OptimizeRx expects revenue of at least $100 million for full-year 2025.

What was OptimizeRx's Q4 2024 Adjusted EBITDA?

Q4 2024 Adjusted EBITDA was $8.8 million, a 53% increase from $5.8 million in Q4 2023.

How much did OptimizeRx's gross profit increase in Q4 2024?

OptimizeRx's Q4 2024 gross profit increased 23% year-over-year to $22.0 million with a 68% margin.